MabCure Inc. Featured in GEN (Genetic Engineering & Biotechnology News)

MabCure, Inc. (“MabCure”), a diagnostic company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, is featured in the September issue of GEN (Genetic Engineering & Biotechnology News). The article, written by MabCure CEO, Dr. Amnon Gonenne, entitled “Searching for Appropriate Cancer Biomarkers,” describes how tumor-specific antibodies could positively impact diagnosis, imaging, and therapy.

“Cancer biomarker discovery has been hampered by the heterogeneity of the diseases known as cancer,” Dr. Gonenne writes. “Even within one cancer type, for example breast, several distinct clinical types exist; moreover, within these researchers have found dozens of genotypic differences. Despite these challenges, the search goes on for these important diagnostic tools.” The article goes on to detail some of the challenges and controversies surrounding the prostate-specific antigen (PSA) test for prostate cancer, and the need to develop cancer-specific antibodies against lethal cancers. “Cancer-specific antibodies may help change the molecular diagnosis and treatment of cancer. If produced at a reasonable cost, such antibodies may be able to improve sensitivity and specificity for cancer screening and diagnosis as well as monitoring of therapy.”

“I am very pleased to see MabCure appear in a publications as prestigious as GEN, and was happy to contribute the article,” said Dr. Amnon Gonenne, MabCure’s President and CEO. “Telling the story and reaching audiences are important parts of the job.”

The GEN article can be read in its entirety at: http://www.genengnews.com/articles/chitem.aspx?aid=3022.

For more news and information on MabCure Inc., please visit www.IRGnews.com/coi/MBCI where you can find the CEO’s video, a fact sheet on the company, investor presentations, and more.

About GEN

Genetic Engineering & Biotechnology News (GEN), the only high-frequency publication dedicated to biotech news, from bench to business, was introduced in 1981 as the first biotechnology trade publication. Now in its twenty-seventh year, GEN retains its position as the most widely read biotechnology publication around the globe.

Published twenty-one times a year, GEN’s unique news and technology content focus includes the entire bioproduct life cycle from early-stage R&D to applied research and bioprocess through to commercialization. GEN is the only publication that provides the full range of the biotechnology market coverage in areas such as omics, drug and biomarker discovery, bioprocessing, clinical research, molecular diagnostics, and biobusiness. For more information, visit http://www.genengnews.com.

About MabCure Inc.

MabCure is a biotechnology company whose vision is to change the perception of cancer as being a largely incurable disease. MabCure owns proprietary technology for the creation of unique and highly specific monoclonal antibodies (MAbs), which will be developed as diagnostic tools, imaging agents, and drugs to treat lethal cancers. MabCure initial goal is to develop its novel MAbs as diagnostic tools for the detection of Ovarian and Prostate cancers at an early stage, when these diseases are still localized and highly curable. For further information visit the Company’s website www.mabcure.com.

This news release contains “forward-looking statements”. Statements in this news release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the change of business focus of the management of the Company or the University and the inability of the Company or the University to pursue its current objectives. These forward-looking statements are made as of the date of this news release and the Company or the University assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements.

MabCure (CE) (USOTC:MBCI)
Historical Stock Chart
From Jun 2024 to Jul 2024